<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-056809</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Vigabatrin toxic retinopathy</dc:title>
<dc:description xml:lang="en">Case report: We report a case of a 63-year-old    patient with epilepsy treated with vigabatrin, who    was seen because of diminished visual acuity. Examination    showed a toxic retinopathy with optic nerve    pallor and severely constricted visual fields. One    year after cessation of the vigabatrin, no change in    the perimetric constriction had occurred.    Discussion: Ophthalmologists and neurologists    need to be aware of the possibility of retinal toxicity    due to the use of vigabatrin. It is still unclear as to    which ophthalmogic assessment is of the most diagnostic    value; however visual field examination    covering the peripheral 60º and optical coherence    tomography could be most useful for the screening    of patients using this agent</dc:description>
<dc:creator>Suárez-Baraza, J</dc:creator>
<dc:creator>Suárez-Parra, S</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Paciente epiléptico de 63 años en tratamiento    con vigabatrina que refería déficit de agudeza    visual. Presentaba una retinopatía tóxica con    palidez papilar e importante retracción del campo    visual. Tras un año de suspensión del tratamiento    persistía la retracción campimétrica.    Discusión: Neurólogos y oftalmólogos debemos    concienciarnos del potencial efecto retinotóxico de    la vigabatrina. No hay consenso en cuanto a la    estrategia de screening a utilizar. Una evaluación    campimétrica hasta los 60º y una tomografía óptica    de coherencia (OCT) parecen ser test diagnósticos    sensibles en el screening de pacientes que toman    vigabatrina</dc:description>
<dc:source>Arch Soc Esp Oftalmol;82(11): 711-714, nov. 2007. ilus</dc:source>
<dc:identifier>ibc-056809</dc:identifier>
<dc:title xml:lang="es">Retinopatía tóxica por vigabatrina</dc:title>
<dc:subject>^d3954^s22012</dc:subject>
<dc:subject>^d3954^s22016</dc:subject>
<dc:subject>^d38335^s22074</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d54195^s22066</dc:subject>
<dc:subject>^d54195^s22074</dc:subject>
<dc:subject>^d38335^s22045</dc:subject>
<dc:subject>^d3942^s22012</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d34388^s22073</dc:subject>
<dc:subject>^d38335^s22066</dc:subject>
<dc:subject>^d34388^s22020</dc:subject>
<dc:subject>^d2256^s22073</dc:subject>
<dc:subject>^d38335^s22039</dc:subject>
<dc:subject>^d2256^s22020</dc:subject>
<dc:type>article</dc:type>
<dc:date>200711</dc:date>
</metadata>
</record>
</ibecs-document>
